Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Reaffirmed by HC Wainwright

Oncolytics Biotech (NASDAQ:ONCY)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 428.93% from the company’s current price.

Oncolytics Biotech Stock Performance

ONCY traded up $0.02 during trading hours on Thursday, reaching $0.95. The company’s stock had a trading volume of 104,700 shares, compared to its average volume of 265,152. Oncolytics Biotech has a 52 week low of $0.85 and a 52 week high of $2.30. The company’s 50-day moving average is $0.99 and its 200-day moving average is $1.04. The firm has a market cap of $72.14 million, a PE ratio of -3.15 and a beta of 1.80.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. During the same period in the prior year, the firm posted ($0.09) earnings per share. Equities analysts anticipate that Oncolytics Biotech will post -0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oncolytics Biotech

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC bought a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech as of its most recent filing with the Securities & Exchange Commission. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.